Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 6Active not recruiting 5Terminated 2Not yet recruiting 2Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Clear-cell metastatic renal cell carcinoma 2Carcinoma, Renal Cell 2

Interventions

Specimen Handling 8Nivolumab 6pembrolizumab 4lenvatinib 3Ipilimumab 3Biopsy 3Axitinib 3vorolanib 2fludarabine 2cabozantinib 2anlotinib 2Sunitinib 2Nephrectomy 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2CTLA-4 Antigen 2toripalimab 1tivozanib 1sodium-iodide symporter 1sintilimab 1pazopanib 1fludarabine phosphate 1cemiplimab 1bemarituzumab 1belzutifan 1balstilimab 1Zoledronic Acid 1Saline Solution 1Rubidium-82 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Renal Cell × CTLA-4 Antigen × Clear all
NCT07510334 2026-04-03

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Mayo Clinic

Phase 2 Not yet recruiting
18 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network

Phase 3 Not yet recruiting
718 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡